Replies to post #188412 on Biotech Values

[dewophile]

I don't think any regimen with their NS5A is worth pursuing - too late to market and doesn't fill any unmet need (like harvoni/viekira failures)
a nuke (especially differentiated from sofo) or cyclophilin could be valuable in harvoni failures with a PI (or PI/ns5a combo)
JMO